SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer
The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide prostate cancer treatment, featuring talazoparib (...
Trump Economic Revival: Key Policies and Impacts from Davos 2026
Trump's Davos 2026 Economic Revival: Claimed Policy Impacts and Metrics
In his special address at the World Economic Forum's Annual Meeting 2026 in Davos, Switzerland, U.S. President Donald J. Trump highlighted t...
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
Pioneering Alzheimer's Care Innovation in Europe
Alzheimer's care innovation is transforming Europe's approach to the disease, shifting from policy discussions to real-world implementation of disease-modifying therapies. With 10 milli...